---
layout: default
title: Enzalutamide
parent: 僅模型預測 (L5)
nav_order: 229
evidence_level: L5
indication_count: 7
---

# Enzalutamide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Enzalutamide: From Prostate Cancer to Prostate/Brain Cancer Susceptibility

## One-Sentence Summary

Enzalutamide is an androgen receptor (AR) antagonist established for prostate cancer treatment — although this Evidence Pack's own `original_indications` field is empty (a flagged data gap), the pack's supporting evidence (see Rank 6 below) independently confirms prostate cancer as its known, approved use. The TxGNN model's top-ranked "new" prediction, **prostate cancer/brain cancer susceptibility**, is a hereditary-risk label rather than a treatable disease entity, and currently has **0 clinical trials** and **0 publications** supporting it. Evidence is essentially absent, and the recommended action is **Hold**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Prostate cancer (confirmed via evidence rationale, cross-checked against Rank 6 candidate; the `original_indications` field itself is a documented data gap — see Conclusion) |
| Predicted New Indication | Prostate cancer/brain cancer susceptibility |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for enzalutamide is not available in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on the supporting rationale text attached to related candidates in this pack, enzalutamide is understood to act as an androgen receptor (AR) antagonist, blocking AR-driven signal transduction — the pathway that drives prostate cancer growth. This mechanism has been clinically validated in prostate cancer (see the Rank 6 evidence set below, which independently confirms this).

The model's top-ranked candidate, however, is not a treatable clinical disease — it is a **cancer susceptibility label** describing hereditary/genetic risk for prostate and brain cancer. AR antagonism has no established mechanistic pathway for altering germline or hereditary cancer *risk*; it only acts on AR-driven tumor cells that already exist. As the evidence pack's own rationale states, this association most likely reflects a knowledge-graph proximity artifact (disease nodes near "prostate cancer" in the graph being scored highly) rather than a genuine pharmacological hypothesis.

For context, five of the seven candidates in this pack (ranks 1–5, 7 — prostate/brain cancer susceptibility, prostate leiomyoma, Brenner tumor, fibroma of prostate, benign prostate phyllodes tumor) are rare, mostly benign conditions with **zero supporting trials or literature**, all scored L5/Hold. Only Rank 6 ("male reproductive organ cancer") carries substantive clinical trial and literature support (L2, Proceed with Guardrails) — but per its own rationale, this candidate effectively re-identifies enzalutamide's already-approved prostate cancer indication rather than representing a novel repurposing opportunity. No candidate in this pack currently constitutes a validated new-indication hypothesis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Enzalutamide is currently **not marketed** in Saudi Arabia under this Evidence Pack's regulatory data (0 authorizations on record). No product license entries are available to list.

---

## Cytotoxicity

Enzalutamide's original approved use is oncologic (prostate cancer), and it is mechanistically an androgen receptor pathway inhibitor rather than a conventional DNA-damaging chemotherapy agent, so this section is included per the antineoplastic-drug criteria.

| Item | Content |
|------|------|
| Cytotoxicity Classification | Targeted therapy (Androgen Receptor signaling inhibitor / non-cytotoxic) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked predicted indication (prostate cancer/brain cancer susceptibility) is a hereditary-risk label rather than a treatable disease, with zero supporting clinical trials or literature (L5). Combined with a Blocking-severity data gap on the TFDA/regulatory package insert (DG001) — which prevents any initial safety assessment (S1) — this candidate cannot proceed past the current stage.

**To proceed, the following is needed:**
- TFDA/regulatory package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action (MOA) data via DrugBank — currently a High-severity data gap (DG002)
- Correction of the `original_indications` metadata field, which is empty despite the evidence pack's own rationale independently confirming prostate cancer as the approved use — this discrepancy should be resolved before further scoring
- If repurposing is still of interest, re-scope away from Rank 1–5 and 7 (no evidence base) and clarify whether Rank 6 ("male reproductive organ cancer") represents a genuinely new use or simply restates the existing approved indication, since current evidence indicates the latter
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

